Comprehensive management of resectable gastric cancer: Requirement for optimal clearance, containment and perioperative intraperitoneal chemotherapy

Clinical and Translational Oncology

Volumn 2, Issue 3, 2000, Pages 129-140

  Moreno, Santiago González ^a   Sugarbaker, Paul H ^a  

^a WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

Cytoreductive surgery; Gastric cancer; Intraperitoneal chemotherapy; Peritonectomy; Review

Indexed keywords

EID: 0006539178     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Landis SH, Murray T, Bolden T, Wingo PA. Cancer Statistics, 1999. CA Cancer J Clin 1999; 49: 8-31
2. Akoh, JA, Macintyre IM. Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br J Surg 1992; 79: 293-299
3. Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H. Surgical treatment for gastric cancer: the Japanese approach. Semin Oncol 1996; 23: 360-368
4. Bonenkamp JJ, Van De Velde CJH, Kampschoer MD, Hermans J, Hermanek P, Bemelmans M et al. Comparison of factors influencing the prognosis of Japanese, German and Dutch gastric cancer patients. World J Surg 1993; 17: 410-415
5. Hundahl SA, Stemmermann GN, Oishi A. Racial factors cannot explain superior Japanese outcomes in stomach cancer. Arch Surg 1996; 131: 170-175
6. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 1: 1441-1447
7. Kelsen DP. Adjuvant and neoadjuvant therapy for gastric cancer. Semin Oncol 1996; 23: 379-389
8. Minsky BD. The role of radiation therapy in gastric cancer. Semin Oncol 1996; 23: 390-396
9. Nio Y, Sato Y, Nagami N, Teramoto M, Inoue Y, Yano S et al. Neoadjuvant chemotherapy of gastric cancer with oral UFT (amixture of uracil and fturafur) during the waiting period for surgery. Anticancer Res 1998; 18: 523-530
10. Crookes P, Leichman C, Leichman L, Tan M, Laine L, Stain S et al. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal chemotherapy: a final report. Cancer 1997; 79: 1767-1775
11. Kondo K, Murase M, Yokoyama Y, Kato J, Hibi K, Kasai Y et al. Neoadjuvant chemotherapy in high-grade advanced gastric cancer with protracted infusional 5-fluorouracil and consecutive low-dose cisplatin. Japan J Cancer Chemother 1996; 23: 1299-1303
12. Rosen H. Stomach carcinoma: optimizing therapy by neoadjuvant or adjuvant therapy?. Zentralblatt fur Chirurgie 1999; 124: 387-393
13. Ausch C, Rosen H, Schiessel R. The value of adjuvant and neoadjuvant chemotherapy in treatment of stomach carcinoma. Wiener Klinische Wochenschrift 1996; 108: 496-504
14. Meyer HJ, Opitz GJ, Jahne J, Wilke H. Hypothetical and reliable aspects of pre, intra and postoperatice adjuvant therapy of stomach carcinoma. Langenbecks Arch Surg 1998; 115: 312-317
15. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int J Rad Oncol Biol Phys 1990; 19: 1357-1362
16. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Rad Oncol Biol Phys 1982; 8: 1-11
17. Wisbeck WM., Becher E.M., Russell A.H. Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologist. Radiother Oncol 1986; 7: 13-18
18. Bonenkamp JJ, Songun I, Hermans J, Van De Velde CJH. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Br J Surg 1996; 83: 672-674
19. Suzuki T, Ochiai T, Hayashi H, Hori S, Shimada H, Isono K. Peritoneal lavage cytology findings as prognostic factor for gastric cancer. Semin Surg Oncol 1999; 17: 103-107
20. Yonemura Y, Nojima N, Kawamura T, Kim BS, Fujita H, Nozaki S et al. Mechanisms of the formation of peritoneal dissemination. En: Yonemura Y, editor. Peritoneal dissemination: molecular mechanisms and the latest therapy. Kanazawa: Maeda Shoten Co., Ltd., 1997; 1-46
21. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. En: Sugarbaker PH, editor. Peritoneal carcinomatosis: principles of management. Boston: Kluwer Academic Publishers, 1996; 79-100
22. a ed.). Tokio: Kanehara, 1999
23. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993; 218: 583-592
24. Sugarbaker PH. Laser-mode electrosurgery. En: Sugarbaker PH, editor. Peritoneal carcinomatosis: principles of management. Boston: Kluwer Academic Publishers, 1996; 375-386
25. Sugarbaker PH. Comprehensive management of microscopic residual disease in colorectal cancer. J Microwave Surg 1999; 17: 15-31
26. Smith JW, Brennan MF. Surgical treatment of gastric cancer. Proximal, mid and distal stomach. Surg Clin North Am 1992; 72: 381-399
27. Karpeh MS Jr, Brennan MF. Gastric carcinoma. Ann Surg Oncol 1998; 5: 650-656
28. Kim JP. Surgical results in gastric cancer. Semin Surg Oncol 1999; 17: 132-138
29. Bonenkamp JJ, Hermans J, Sasako M, Van De Velde CJH, Welvaart K, Songun I et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914
30. Cushieri A, Weeden S, Fielding J, Bansewicz J, Craven J, Joypaul V et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999; 79: 1522-1530
31. Cushieri A, Fayers P, Fielding J, Craven J, Bansewicz J, Joypaul V et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet 1996; 347: 995-999
32. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JTM et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cabncer in 996 Dutch patients. Lancet 1995; 345: 745-748
33. Griffith JP, Sue-Ling H, Martin I, Dixon MF, McMahon MJ, Axon ATR et al. Preservation of the spleen improves survival after radical surgery for gastric cancer. Gut 1995; 36: 684-690
34. Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H, Okajima K. Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 1995; 16: 532-536
35. Brennan MF. Lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 956-958
36. Elias D. Reflections and proposals for the worldwide standarization of lymphadenectomy for gastric carcinoma. Semin Surg Oncol 1999; 71: 120-122
37. Brennan MF, Karpeh MS Jr. Surgery for gastric cancer: the American view. Semin Oncol 1996; 23: 352-359
38. Meyer S, Jahne MD. Lymph node dissection for gastric cancer. Semin Surg Oncol 1999; 17: 117-124
39. Pacelli F, Doglietto GB, Bellantone R, Alfieri S, Sgadari A, Crucciti F. Extensive versus limited lymph node dissection for gastric cancer: a comparative study of 320 patients. Br J Surg 1993; 80: 1153-1156
40. Smith JW, Shiu MH, Kelsey L, Brennan MF. Morbidity of radical lymphadenectomy in the curative resection of gastric carcinoma. Arch Surg 1991; 126: 1469-1473
41. Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P, Meyer H. Prognostic factors in gastric carcinoma: results of the German Gastric Carcinoma Study 1992. Cancer 1993; 72: 2089-2097
42. Sue-Ling HM. Radical surgery is essential for treating gastric cancer. Eur J Surg Oncol 1994; 20: 179-182
43. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979; 39: 3861-3865
44. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983: 1488-1492
45. Averbach A, Jacquet P. Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Br J Surg 1996; 83: 726-733
46. Sindelar WF, Kinsella TJ, Tepper JF, DeLaney T, Maher MM, Smith R et al. Randomized trial of intraoperative radiotherapy in carcinoma of the stomach. Am J Surg 1993; 165: 178-182
47. Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62: 1-11
48. a ed.) Grand Rapids, Michigan: The Ludann Company, 1998
49. Yonemura Y. Principles of the treatment of peritoneal dissemination. En: Yonemura Y, editor. Peritoneal dissemination: molecular mechanisms and the latest therapy. Kanazawa: Maeda Shoten Co., Ltd., 1997; 175-190
50. Koga S, Hamazoe R, Maeta M, Shimizu N, Marakami A, Wakatsuki T. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 1988; 61: 232-237
51. Hamazoe R, Maeta M, Kaibara N. Intraperitoneal termochemotherapy for prevention of peritoneal recurrence of gastric cancer. Cancer 1994; 73: 2048-2052
52. Fujimura T, Yonemura Y, Muraoka K, Takamura H, Hirono Y, Sahara H et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg 1994; 18: 150-155
53. Yonemura Y, Ninomiya I, Kaji M, Sugiyama K, Fujimura K, Sawa T et al. Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal-invasion positive gastric cancer. World J Surg 1995; 19: 450-455
54. Ikeguchi M, Kondou A, Oka A, Tsujitani S, Maeta M, Kaibara N. Effects of continuous hyperthermic peritoneal perfucion on prognosis of gastric cancer with serosal invasion. Eur J Surg 1995; 161: 581-586
55. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Succesful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999; 85: 529-534
56. Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998; 228: 347-354
57. Kim JY, Rhew CH, Kim KS, Jeong JH. Controlled clinical trial for the gastric carcinoma patients underwent surgery plus IHCP. Seúl, Corea: Third International Gastric Cancer Congress, 27-30 abril, 1999
58. Sautner T, Hofbauer F, Depisch D, Shiessel R, Jakesz R. Adjuvant intraperiotneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994; 12: 970-974
59. Begossi G, Caprino P, Tentes AA, Chang D, Sugarbaker PH. Management of peritoneal seeding from gastric cancer - palliative gastrectomy, peritonectomy and perioperative intraperitoneal chemotherapy. Acta Chir Austr 1999; 31 (Supl 155): 35-38
60. Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH. Indications for early postoperative intraperitoneal chemotherapy in advanced gastric cancer: results of a prospective randomized trial. World J Surg (in press)
61. Hiki Y. Endoscopic diagnosis of mucosal cancer. Semin Surg Oncol 1999; 17: 91-95
62. Siewert JR, Stein HJ, Sendler A, Fink U. Surgical resection for cancer of the cardia. Semin Surg Oncol 1999: 125-131
63. Yu W, Whang I, Averbach A, Chang D, Sugarbaker PH. Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer. Am Surg 1998; 64: 1104-1108
64. Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the Colyseum Technique. Ann Surg Oncol 1999; 6: 790-796
65. Sugarbaker PH, Averbach A, Yonemura Y. Palliation with a glimmer of hope: management of resectable gastric cancer with peritoneal carcinomatosis. En: Kim JP, Min JS, editores. Third International Gastric Cancer Congress. Bolonia, Italia: Monduzzi Editore, 1999; 801-805
66. Ekbom GA, Gleysteen JJ. Gastric malignancy: resection for palliation. Surgery 1980; 88: 476-481
67. Meijer S, De Bakker OJ, Hoitsma HF. Palliative resection in gastric cancer. J Surg Oncol 1983; 23: 77-80
68. Boddie AW, McMurtrey M, Giacco CG, McBride C. Palliative total gastrectomy and esophagogastrectomy. A reevaluation. Cancer 1983; 51: 1195-1200
69. Bozzetti F, Bonfanti G, Audisio RA, Doci R, Dossena G, Gennari L et al. Prognosis of patients after palliative surgical procedures for carcinoma of the stomach. Surg Gynecol Obstet 1987; 164: 151-154
70. Hallissey MT, Allum WH, Roginsky C, Fielding JW. Palliative surgery for gastric cancer. Cancer 1988; 62: 440-444
71. Butler JA, Dubrow TJ, Trezona T, Klassen M, Nejdl RJ. Total gastrectomy in the treatment of advanced gastric cancer. Am J Surg 1989; 158: 602-604
72. Haugstvedt T, Viste A, Eide GE, Soreide O. The survival benefit of resection in patients with advanced stomach cancer: the Norwegian multicenter experience. World J Surg 1989; 13: 617-621
73. Monson JR, Donohue JH, McIlrath D, Farnell MB, Ilstrup DM. Total gastrectomy for advanced cancer. A worthwhile palliative procedure. Cancer 1991; 68: 1863-1868
74. Ouchi K, Sugawara T, Ono H, Fujiya T, Kamiyama Y, Kakugawa Y et al. Therapeutic significance of palliative operations for gastric cancer for survival and quality of life. J Surg Oncol 1998; 69: 41-44
75. Kikuchi S, Tsukamoto H, Mieno H, Sato K, Kobayashi N, Shimao H et al. Results of resection of gastric cancer with distant metastasis. Hepatogastroenterol 1998; 45: 592-596
76. Bae BJ, Park KH, Sohn SS, Song SK, Yu W. Prognosis of the patients with stage IV gastric cancer. Second International Gastric Cancer Congress. Munich (Germany), April 27-30, 1997. Bolonia, Italia: Monduzzi Editore, 1997; 175-179
77. Fujimoto S, Shrestha RD, Kokubun M, Kobayashi K, Kiuchi S, Konno C et al. Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. Ann Surg 1990; 212: 592-596
78. Hirose K, Katayama K, Iida A, Yamaguchi A, Nakagawara G, Umeda S et al. Efficacy of continuous hyperthermic periotneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. Oncology 1999; 57: 106-114
79. Ohta K, Ohyama S, Takahashi M, Nakajima T. Usefulness of intraperitoneal administration of cisplatin using a reservoir for advanced gastric cancer complicated by peritoneal dissemination. Seúl, Corea: Third International Gastric Cancer Congress; 27-30 abril, 1999
80. Yonemura Y, Fujimura T, Fushida S, Takegawa S, Kamata T, Katayama K et al. Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J Surg 1991; 15: 530-536
81. Yonemura Y, Fujimura T, Nishimura G, Falla R, Sawa T, Katayama K et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996; 119: 437-444
82. Yoo CH, Noh SH, Shin DW, Chung HC, Kim JH, Roh JK et al. Early postoperative intraperitoneal chemotherapy (EPIC) for advanced gastric cancer. Seul, Korea: Third International gastric Cancer Congress, 27-30 abril, 1999
83. Yonemura Y, Fujimura T, Fushida S, Fujita H, Bando E, Nishimura G et al. A new surgical approach (peritonectomy) for the treatment of peritoneal dissemination. Hepatogastroenterol 1999; 46: 601-609
84. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T, Ohkubo H. Treatment failures after intraperitoneal hyperthermic perfusion combined with surgery for advanced gastric cancer. Reg Cancer Treat 1996; 9: 164-169
85. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221: 29-42
86. Gómez-Portilla A, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg 1999; 23: 23-29
87. Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer 1999; 35: 413-419